|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- Special Health Authorities
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
- GP - Locum
- GP Practices
- Community Pharmacy
- Primary Care Networks
- GP Practices 1
|
| Title: |
|
COVID-19 Therapeutic Alert - Antimicrobials (azithromycin and doxycycline) Not Beneficial in the Management of COVID-19 (SARS-CoV-2) Positive Patients
|
| Broadcast content: |
|
The recent announcement from the National Institute for Health Research (NIHR) supported PRINCIPLE trial demonstrates the vital importance of robust clinical trials in our response to COVID-19. The lack of beneficial effect in patients aged over 50 who are treated with either azithromycin or doxycycline at home in the early stages of COVID-19 suggests that these antibiotics should not be used within primary care for the treatment of COVID-19 unless there is an additional licensed indication. Overuse of antibiotics in the community can contribute to antimicrobial resistance.
|
| Additional information: |
|
NHS England and NHS Improvement Regional Offices: please cascade this alert to Community Pharmacy.
|